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Abstract
Introduction. Atrial fibrillation (AF) is the most common type of supraventricular arrhythmia. Electrical cardioversion is 
a non-pharmacological method of restoring sinus rhythm in AF patients. The role of transoesophageal echocardiography 
(TEE) in patients subjected to electrical cardioversion has not yet been fully established.
The objective of this study was to assess the safety of electrical cardioversion procedures in AF patients who had re-
ceived novel oral anticoagulants for at least 21 days prior to the procedure, and in whom electrical cardioversion was 
carried out without previous TEE examination.
Material and methods. The study population consisted of 132 patients receiving non-vitamin K antagonist oral anti-
coagulants (NOACs) and subjected to electrical cardioversion procedures at a district hospital cardiology department. 
Patients with valvular AF and patients receiving NOACs in an irregular fashion were excluded from the study. The inci-
dence of thromboembolic and haemorrhagic complications was assessed over a 30-day follow-up period.
Results. In a group of 132 patients treated with NOACs, rivaroxaban was used in 65 (49.2%) patients, dabigatran was 
used in 62 (47.0%) patients, and apixaban was used in five (3.8%) patients. No thromboembolic or haemorrhagic com-
plications were observed in the study group over the hospitalisation period or the 30-day follow-up period.
Conclusions. NOACs are effective and safe in the premedication of AF patients prior to electrical cardioversion procedu-
res. Electrical cardioversion without prior TEE is a safe method of managing patients receiving regular premedication 
with NOACs for at least 21 days before a sinus rhythm restoration procedure.
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Introduction
Atrial fibrillation (AF) is the most common supraventricular 
arrhythmia. It is estimated to be the cause of one in three 
of all hospitalisations caused by arrhythmias. The incidence 
of AF increases with age and is above 8% in patients aged 
over 80. It is more frequent in men than in women [1]. The 
non-pharmacological method of restoring sinus rhythm is 
transthoracic cardioversion with direct current. This can be 
used alone or in combination with anti-arrhythmic drugs 
[2, 3]. In the retrospective analysis of Gallagher et al. [4] 
including more than 2,600 electrical cardioversions, it was 
proved that an international normalised ratio (INR) > 2.5 
obtained before the procedure protects the patient from 
thromboembolic complications [0% of cases vs. 0.93% for 
INR 1.5–2.4 (p < 0.012)].
There is also data regarding the safety of using non-
vitamin K antagonist oral anticoagulants (NOACs) in 
patients with AF undergoing electrical cardioversion. Post-
hoc analyses of large studies have shown that dabigatran 
[RE-LY (Randomized Evaluation of Long Term Anticoagulant 
Therapy)], rivaroxaban [ROCKET-AF (Rivaroxaban Once Daily 
Oral Direct Factor Xa Inhibition Compared with Vitamin K 
Antagonism for Prevention of Stroke and Embolism Trial 
in Atrial Fibrillation study)], and apixaban [ARISTOTLE (Api-
xaban for Reduction in Stroke and Other Thromboembolic 
Events in Atrial Fibrillation)] are safe in patients undergoing 
electrical cardioversion, with the risk of thromboembolic 
complications being less than 1% [5–7].
The aim of this study was to assess the safety of elec-
trical cardioversion performed in patients with AF treated 
with NOACs, without a transoesophageal echocardiography 
(TEE) assessment prior to electrical cardioversion.
Materials and methods
The study included patients for whom an elective car-
dioversion was performed and who were treated in the 
Cardiology Unit of The City Hospital between 1 January 
2016 and 31 December 2017. Inclusion criteria were 
persistent AF and the use of NOACs for at least 21 days 
prior to elective cardioversion. Exclusion criteria were the 
following: urgent electrical cardioversion, valvular AF, atrial 
flutter, and non-compliance with NOACs. Transthoracic 
echocardiography was performed in all patients prior to 
cardioversion. Patients signed a statement confirming 
that they were regularly taking the drug. The incidence of 
thromboembolic complications was assessed: ischaemic 
stroke, transient ischaemic episode, peripheral embolism 
as well as bleeding complications during hospitalisation 
after electrical cardioversion and within 30 days after 
electrical cardioversion.
Results
In a group of 170 patients admitted to the Cardiology Unit, 
38 patients (22.4%) received a vitamin K antagonist (VKA) 
to perform an elective cardioversion, and 132 patients 
(77.6%) were treated with NOACs. A further analysis was 
performed on these 132 patients treated with NOACs. In 
this group, dabigatran was used in 62 patients (46.9%), 
rivaroxaban in 65 patients (49.2%), and apixaban in five 
patients (3.9%). Figure 1 shows the dosage of NOAC in 
patients undergoing electrical cardioversion.
The average age among patients treated with NOACs 
was 69.3 years. The majority was male — 78 patients 
(59.1%).
The most common comorbidity in the study group was 
arterial hypertension, which was present in 117 subjects 
(88.6%). Table 1 presents the characteristics of the stu-
died group.
In the study group, the majority of patients were at high 
risk of thromboembolism; the CHADS2 ≥ score was 2 points 
in 80 patients (60.6%), anjd the CHA2DS2VASc score was 
≥ 2 points in 59 patients (44.7%). Table 2 presents the 
scoring in the CHADS2 and CHA2DS2VASc scales.
Figure 1. Dosing of anticoagulants in patients with atrial fibrillation subjected to electrical cardioversion; NOAC — non-vitamin K antagonist 
oral anticoagulant
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Restored sinus rhythm persisting until discharge from 
the hospital was obtained in 107 patients (81.1%).
No thromboembolic complications or haemorrhagic 
complications were observed during hospitalisation after 
cardioversion in patients receiving NOACs.
During the 30-day follow-up, patients undergoing 
electric cardioversion treated with NOACs developed nei-
ther thromboembolic complications nor haemorrhagic 
complications.
Discussion
In the present study, NOACs were received by almost 80% 
of patients in preparation for an elective cardioversion. 
The percentage of patients treated with NOACs has signi-
ficantly increased in recent years, including those being 
prepared for electrical cardioversion. This is due to the 
effectiveness and safety profile of NOACs, as well as to 
a significantly simpler therapy regimen compared to VKA. 
According to the current European Society of Cardiology 
(ESC) guidelines for the treatment of patients with AF, 
NOACs should be preferred among patients starting anti-
coagulant therapy [8].
Gawałko et al. [9] in a group of 859 patients showed 
that NOACs were used in 49% of patients undergoing elec-
tive cardioversion or ablation due to AF. Fredriksen et al. 
[10] in a study of 2,150 patients hospitalised for elective 
cardioversion between 2011 and 2016 showed that the 
percentage of patients treated with NOACs was lower than 
in the present study, and was 32%. Also, Papp et al. [11] 
showed that in a group of 1,101 patients, NOAC before 
cardioversion was used in 32% of patients. In a work by 
American authors, in a population of 5,320 patients hospi-
talised in 2011–2013, the percentage of patients treated 
with NOACs was 20% [12].
Most data on sinus rhythm restoration in patients 
treated with s comes from a subanalysis of large studies. 
Dabigatran was the first NOAC registered for use in patients 
undergoing cardioversion. Among a RE-LY population, 
1,983 cardioversions were performed in 1,270 patients. 
Thromboembolism after 30 days cardioversion was ob-
served in 0.8% of patients treated with dabigatran 110 mg 
bis die (BD), in 0.3% of patients treated with dabigatran 
150 mg BD, and in 0.6% of patients receiving warfarin. 
There were no differences in the incidence of major bleeding 
complications in individual groups of patients [5]. Apixaban 
was registered for use in patients undergoing cardioversion 
based on a subanalysis of the ARISTOTLE study involving 
540 patients. When comparing the groups treated with 
warfarin and apixaban, cardiovascular events and haemorr-
hagic complications were identical [7]. In subanalysis of 
the ROCET-AF study, rivaroxaban has been shown to be as 
effective and as safe as warfarin in AF patients undergoing 
electrical cardioversion [6]. The X-VeRT (Explore the Efficacy 
and Safety of Once-daily Oral Rivaroxaban for the Prevention 
of Cardiovascular Events in Subjects With Nonvalvular Atrial 
Fibrillation Scheduled for Cardioversion) study was the first 
randomised trial to confirm the efficacy and safety of rivaro-
xaban in patients undergoing early electrical cardioversion 
(1–5 days after randomisation) and delayed electrical car-
dioversion (308 weeks after randomisation) [13].
The importance of TEE in patients treated with NOACs 
undergoing electric cardioversion has not been clearly 
established to date. Experts recommend the performance 
of TEE for patients with cardioversion if no effective anti-
coagulation was found within 21 days in recommendations 
for the treatment of patients with AF [8]. However, they do 
not directly address patients receiving NOACs. In the RE-LY 
subanalysis of patients undergoing cardioversion, TEE was 
performed in 21% of subjects [5]. In the ARISTOTLE study 
Table 1. Study group characteristics
Comorbidity Patients treated with NOAC 
N = 132 
Arterial hypertension 117 (88.6%)
Ischaemic heart disease 68 (51.51%)
Diabetes 34 (25.6%)
Transient ischaemic attack 19 (14.39%)
Ischaemic stroke 18 (13.6%)
Myocardial infarction 16 (12.1%)
COPD 17 (12.87%)
NOAC — non-vitamin K antagonist oral anticoagulant; COPD — chronic obstructive pulmonary 
disease
Table 2. Scoring results in CHADS2, CHA2DS2VASc scales for pa-
tients undergoing electric cardioversion
Scale Patients treated with NOAC 
N = 132 
CHADS2 score (points):
• 0 16 (12.1%)
• 1 36 (27.3%)
• ≥ 2 80 (60.6%)
CHA2DS2VASc score (points):
• 0 (or 1 only if female) 57 (43.2%)
• 1 16 (12.1%)
• ≥ 2 59 (44.7%)
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Streszczenie
Wstęp. Migotanie przedsionków (AF) to najczęstszy typ arytmii nadkomorowej. Niefarmakologiczną metodą przywraca-
nia zatokowego rytmu serca u chorych z AF jest kardiowersja elektryczna. Pozycja przezprzełykowego badania echokar-
diograficznego (TEE) u chorych poddawanych kardiowersji elektrycznej nadal nie jest ostatecznie ustalona.
Celem pracy była ocena bezpieczeństwa kardiowersji elektrycznej u pacjentów z AF stosujących co najmniej 21 dni 
doustne antykoagulanty niebędące antagonistami witaminy K (NOAC), u których kardiowersję elektryczną wykonano 
bez poprzedzającej TEE.
Materiał i metody. Badaniem objęto 132 chorych leczonych NOAC poddawanych kardiowersji elektrycznej na oddziale 
kardiologii szpitala powiatowego. Z badania wyłączono chorych z zastawkowym AF oraz nieregularnie przyjmujących 
NOAC. Oceniono częstość występowania powikłań zakrzepowo-zatorowych oraz krwotocznych w obserwacji 30-dniowej.
Wyniki. W grupie 132 chorych leczonych NOAC 65 chorych (49,2%) otrzymywało riwaroksaban, 62 chorych (47,0%) 
dabigatran, a 5 chorych apiksaban (3,8%). W okresie szpitalnym i w czasie 30-dniowej obserwacji w badanej grupie nie 
stwierdzono powikłań zakrzepowo-zatorowych ani powikłań krwotocznych.
Wnioski. Leki z grupy NOAC są skuteczne i bezpieczne w przygotowaniu chorych z AF do kardiowersji elektrycznej. 
U chorych regularnie stosujących NOAC przez co najmniej 21 dni przed planowanym przywróceniem rytmu zatokowego 
bezpiecznym postępowaniem jest wykonywanie kardiowersji elektrycznej bez poprzedzającej TEE.
Słowa kluczowe: TEE, kardiowersja elektryczna, NOAC
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